Australia markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
72.56-0.95 (-1.29%)
At close: 04:00PM EDT
72.50 -0.06 (-0.08%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close73.51
Open73.51
Bid72.55 x 700
Ask72.59 x 400
Day's range71.96 - 73.74
52-week range62.07 - 87.86
Volume5,570,664
Avg. volume7,615,551
Market cap90.399B
Beta (5Y monthly)0.20
PE ratio (TTM)201.56
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.08 (4.24%)
Ex-dividend date14 June 2024
1y target estN/A
  • Business Wire

    Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

    FOSTER CITY, Calif., July 17, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this transition over the next several months.

  • Business Wire

    Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

    FOSTER CITY, Calif., July 16, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany, and virtually, from July 22-26. As the leading innovator in HIV, Gilead will share new data from its research and development programs and Gilead-supported collaborations that unite leading scientific innovation and partnership aimed at ending the HIV epidemic.

  • Business Wire

    Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

    FOSTER CITY, Calif., June 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.